libtayo monotherapi improv surviv non-smal
takeaway encourag reduct risk death
libtayo cemiplimab monotherapi vs platinum doublet chemotherapi phase non-
small cell lung cancer nsclc studi front-lin patient anticip libtayo sbla
file subsequ approv earli
libtayo reduc risk death trial stop earli due strong
phase trial libtayo vs chemotherapi front-lin lung cancer stop earli
due strong benefit libtayo expect take front-lin share
bmi nivolumab lung cancer independ data monitor committe idmc
protocol-specifi interim analysi found libtayo monotherapi reduc
risk death ci compar platinum
chemotherapi note chemotherapi patient abl crossov libtayo
diseas progress new safeti signal emerg trial look forward
see detail data present futur medic meet includ
degre crossov absolut magnitud surviv benefit
libtayo nsclc data compar keytruda view
libtayo vs chemotherapi demonstr hr ci overal
surviv vs hr ci keytruda
importantli compar hr patient express await
addit data libtayo studi better understand magnitud clinic
benefit includ os durat progression-fre surviv efficaci data
chemotherapi arm also await crossover-adjust hr data addit detail
degre crossov occur studi current anticip sny/
submit applic fda ema expand libtayo label includ
nsclc expect approv
regeneron sanofi also test libtayo chemotherapi libtayo
chemotherapi yervoy vs chemotherapi front-lin nsclc patient
express could open larger market opportun especi
bmi opdivo libtayo chemotherapi combin data would open full rang
front-lin nsclc patient libtayo treatment combin libtayo
monotherapi data disclos today addit libtayo chemotherapi yervoy
regimen would provid uniqu competit angl opdivo yervoy
disappoint front-lin nsclc
maintain buy rais pt
maintain buy rate increas pt base
posit readout libtayo nsclc go forward continu expect strong
growth dupix libtayo eylea diabet indic also
encourag sanofi agreement restructur could give wholli
own product increas oper margin see pipelin
potenti addit indications/opportun eylea market product
addit sourc valu stock
biotech
discov invent manufactur
commerci medicin treat seriou
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object
view compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
buy unchang target price april
may dataphas data osteoarthr knee hipfda decis sbla expand ad indic pediatr patient data potenti phase data r/r b-cell malignanciesphas data potenti phase data r/r mmphase dataphas portion data eosinophil esophag patientsphas studi asthma pediatr patient year datapivot phase data patientsphas data regeneron pharmaceut
buy unchang target price april
buy unchang target price april
fy producteyleau ex-u arcalystu ex-u revenues- libtay ex-u praluentu net product sale book praluentu ex-u ww zaltrapex-u us ww kevzarau ex-u dupixentu ex-u regeneron pharmaceut
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may
obtain contact canaccord genuiti sale person author analyst whose contact inform appear front page report
buy unchang target price april
fy statementnet product sanofi collabor bayer healthcar collabor collabor total good option expensegross oper expensesresearch develop research develop sell gener administr sell gener administr collabor oper incom expens total oper profit loss oper profit loss incom expens incom expens loss earli extinguish debtpre-tax incom pre-tax incom tax rate tax expens benefit tax rate tax expens benefit net incom loss adjust net net incom loss ep fulli ep fulli figur balanc sheet
buy unchang target price april
fy pharmaceut balanc sheetasset cash equival market secur account receiv trade account receiv sanofi account receiv bayer defer tax assets- prepaid expens current asset total current asset restrict cash market secur market secur properti plant equip cost net accumul defer tax asset total asset liabil account payabl accru expens defer revenu sanofi current portion liabil defer revenu current portion facil leas oblig current portion current liabilities- total current liabil facil leas oblig defer revenu sanofi liabil defer revenu long term liabil total liabil commit conting total stockhold equiti total liabil stockhold equiti figur flow
buy unchang target price april
fy statement flow net incom adj reconcil net loss net cash use provid oper activities- depreci non-cash compens non-cash interest expense- loss earli extinguish debt- net realiz loss gain market securities- non-cash charg expens defer chang asset liabil decreas increas account increas increas decreas prepaid expens decreas increas defer increas account payabl accru expens total flow purchas market sale matur market purchas restrict market securities- decreas increas restrict cash- capit increas restrict cash- other- flow repurchas repay note payable- proce connect facil leas obligations- payment connect facil leas obligations- net proce issuanc common payment common stock tender employe tax payment connect reduct outstand warrants- net proce issuanc convert debt- proce connect issuanc warrants- payment connect capit leas obligations- payment connect convert debt- payment connect purchas convert note hedges- excess tax benefit stock-bas compensation- repurchas common flow net increas cash cash cash equival begin cash equival end regeneron
